$0.54-0.04 (-6.27%)
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance.
ENvue Medical, Inc. in the Healthcare sector is trading at $0.54 with a market capitalization of $5M. The stock is currently near its 52-week low of $0.54, remaining 82.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $653,000β | $312,000β | $722,000β | $494,000β | $1.02M |
| Gross Profit | -$55,000β | -$370,000β | $189,000β | -$35,000β | $369,000 |
| Operating Income | -$3.71Mβ | -$3.66Mβ | -$2.25Mβ | -$3.98Mβ | -$1.85M |
| Net Income | -$3.82Mβ | -$12.85Mβ | $510,000β | -$3.97Mβ | -$1.87M |
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product...
ENvue Medical Inc. on Tuesday said an integrated nonprofit health system operating 12 hospitals across Virginia and North Carolina renewed its contract with the company for another three years, extending the relationship through 2028. ENvue Medical Extends Health System Agreement...
Nu Holdings Ltd. 45,229,536 14.51
Insiders were net buyers of ENvue Medical, Inc.'s ( NASDAQ:FEED ) stock during the past year. That is, insiders bought...
ENvue Medical (FEED) announced the launch of a new development and integration program leveraging vibration-based technology from its NanoVibronix division to address pain and discomfort associated with indwelling nasogastric tubes. Doron Besser, MD, CEO of ENvue Medical, commented, βWe believe that this program represents a disciplined platform expansion initiative focused on improving the overall enteral care experience by addressing patient comfort during prolonged NG tube use. While this ini